Advanced epithelial ovarian cancer in a group of colombian patients
Keywords:
Ovarian neoplasms, Therapy, Neoadj uvant therapy, SurgAbstract
Objective: To describe fourteen years of experience of in the treatment of advanced stagesof epithelial ovarian cancer in the National Cancer Institute of Colombia
Methods: A retrospective observational case series including patients with epithelial ovarian cancer in stages III and IV, who received primary treatment in National Cancer Institute of Colombia between January 1st, 1997 and December 31th, 2011.
Results: A total of 119 patients were identifed durin the study period. With a median age of 56 years, most patients showed functional status compromise (63.9%) and hypolbuminemia (82.4%). The most common histological type was serous adenocarcinoma (62.2%) and there was poorly differentiated histological grade in 63.3%of cases. Almost all (94.1%) patients had peritoneal surfaces compromise with involvement of the upper abdomen in 38.7% and extra-abdominal disease in 29.4%. Treatment with primary surgery plus adjuvant chemotherapy was performed on 89.1%, achieving optimal cytoreduction in 25.2% 29% of cases showed progression during treatment, and 57% of them relapsed. The median disease-free survival was 16.61 months, and theoverall survival was 28.93 months.
Conclusions: In our setting, patients with advanced epithelial ovarian cancer have a high tumor burden and aggressive behavior of the disease, reflected in a poor oncological outcome.
Author Biographies
Mauricio González, Instituto Nacional de Cancerología
Clínica de Ginecología Oncológica, Instituto Nacional deCancerología, Bogotá Colombia
Carlos A. Barrera, Instituto Nacional de Cancerología
Instituto Nacional de Cancerología, Bogotá, Colombia
Fellow de Ginecología Oncológica, Universidad Militar Nueva Granada, Bogotá, Colombia
Juan S. Castillo, Instituto Nacional de Cancerología
Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, Colombia
References
Ferlay J, Shin HR, Bray F, et al. Cancer incidence and mortality worldwide. GLOBOCAN 2008. IARC Cancer Base N.° 10. Disponible en: http://globocan.iarc.fr/
Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematology/ oncology clinics of North America. 2012; 26:1-12.
https://doi.org/10.1016/j.hoc.2011.10.009
República de Colombia, Ministerio de la Protección Social, Instituto Nacional de Cancerología. Anuario Estadístico 2010; Bogotá: Legis; 2010.
Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematology/oncology clinicsof North America. 2012;26:93-109.
https://doi.org/10.1016/j.hoc.2011.10.004
Tavassoli FA, Devilee P. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
Elattar A , Bryant A , Ba W-roach , Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews. 2011: CD007565
https://doi.org/10.1002/14651858.CD007565.pub2
Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer. 2011;47 Suppl 3: S88-92.
https://doi.org/10.1016/S0959-8049(11)70152-6
Zivanovic O, Aldini A, Carlson JW, Chi DS. Advanced cytoreductive surgery: American perspective. Gynecologic Oncology. 2009;114(2 Suppl):S3-9.
https://doi.org/10.1016/j.ygyno.2008.11.033
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England Journal of Medicine. 2010 (Suppl 2);363:943-53.
https://doi.org/10.1056/NEJMoa0908806
Markman M. Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. Journal of clinical oncology: Oficial Journal of the American Societ y of Clinical Oncology. 2007;25:4168-70.
https://doi.org/10.1200/JCO.2007.11.8992
Mazzeo F, Berlière M, Kerger J, Squifàet J, Duck L, D'Hondt V, et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecologic Oncology. 2003;90:163-9.
https://doi.org/10.1016/S0090-8258(03)00249-X
Kang S, Nam B-H. Does neoadj uvant chemot herapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Annals of surgical oncology. 2009; 16: 2315-20.
https://doi.org/10.1245/s10434-009-0558-6
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England Journal of Medicine. 2010;363:943-53.
https://doi.org/10.1056/NEJMoa0908806
Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic oncology. 2006;103: 1070-6.
https://doi.org/10.1016/j.ygyno.2006.06.025
Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecologic Oncology. 2007;104:480-90.
https://doi.org/10.1016/j.ygyno.2006.11.002
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine D a, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecologic Oncology. 2009;114:26-31.
https://doi.org/10.1016/j.ygyno.2009.03.018
Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecologic oncology. 2012;124:10-4.
https://doi.org/10.1016/j.ygyno.2011.08.014
Vergote I, Weber I, Tjalma W, Van Gramberen, Decloedt J, Van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysisof 285patients. GynecologicOncology. 1998;71:431-6.
https://doi.org/10.1006/gyno.1998.5213
Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, et al. The impact of bulky upper abdominal disease cephalad to the greater ometum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic Oncology. 2008;108:287-92.
https://doi.org/10.1016/j.ygyno.2007.10.001
Chi DS, Eisenhauer EL, Land J, Huh J, Haddad L, Abu-Rustum NR , etal . What is t he optimal goal of primary cytoloreductive surgery for bulky stage III Cepitelial ovarian carcinoma (EOC)? Gynecologic Oncology. 2006;103:559-64.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
